AQST Company Profile and Key Details
Aquestive Therapeutics
Price Chart
Stock Price Today
Aquestive Therapeutics, Inc. (AQST) stock declined over -2.03%, trading at $3.86 on NASDAQ, down from the previous close of $3.94. The stock opened at $3.90, fluctuating between $3.86 and $3.97 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 10, 2026 | 3.90 | 3.97 | 3.86 | 3.86 | 2.07M |
| Feb 09, 2026 | 4.10 | 4.10 | 3.83 | 3.94 | 2.56M |
| Feb 06, 2026 | 3.91 | 4.18 | 3.88 | 4.11 | 2.93M |
| Feb 05, 2026 | 3.91 | 4.03 | 3.78 | 3.84 | 3.94M |
| Feb 04, 2026 | 4.09 | 4.14 | 3.92 | 4.00 | 4.13M |
| Feb 03, 2026 | 4.15 | 4.31 | 4.00 | 4.10 | 7.62M |
| Feb 02, 2026 | 4.00 | 4.39 | 3.79 | 4.10 | 60.9M |
| Jan 30, 2026 | 3.16 | 3.21 | 2.93 | 2.95 | 5.53M |
| Jan 29, 2026 | 3.23 | 3.25 | 3.13 | 3.16 | 3.43M |
| Jan 28, 2026 | 3.48 | 3.50 | 3.20 | 3.24 | 3.78M |
| Jan 27, 2026 | 3.22 | 3.50 | 3.22 | 3.47 | 3.47M |
| Jan 26, 2026 | 3.24 | 3.30 | 3.17 | 3.24 | 2.58M |
| Jan 23, 2026 | 3.25 | 3.38 | 3.23 | 3.24 | 2.58M |
| Jan 22, 2026 | 3.36 | 3.42 | 3.24 | 3.25 | 3.12M |
| Jan 21, 2026 | 3.50 | 3.50 | 3.16 | 3.36 | 5.45M |
| Jan 20, 2026 | 3.29 | 3.55 | 3.21 | 3.48 | 5.2M |
| Jan 16, 2026 | 3.34 | 3.39 | 3.26 | 3.31 | 4.46M |
| Jan 15, 2026 | 3.50 | 3.54 | 3.31 | 3.34 | 4.27M |
| Jan 14, 2026 | 3.32 | 3.60 | 3.32 | 3.52 | 7.05M |
| Jan 13, 2026 | 3.50 | 3.50 | 3.21 | 3.42 | 9.95M |
Contact Details
About Company
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Company Information
| Employees | 142 |
| Beta | 1.66 |
| Sales or Revenue | $50.58M |
| 5Y Sales Change% | -0.746% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
Frequently Asked Questions
Senior Vice President & Chief Financial Officer
Dr. Kenneth Truitt M.D.
Chief Medical Officer
Mr. Kenneth W. Marshall
Senior Vice President & Chief Commercial Officer
Dr. Stephen Wargacki
Senior Vice President of R&D
Mr. Alexander Mark Schobel
Chief Innovation & Technology Officer
Mr. Keith J. Kendall
Consultant
Dr. Eric Dadey Ph.D.
Senior Vice-Pres of R&D
Dr. Gary H. Slatko M.D., MBA
Chief Medical Officer
Ms. Cassie Jung
Senior Vice President of Operations
Dr. Carl N. Kraus M.D.
Chief Medical Officer
Mr. Daniel Barber
Chief Executive Officer, Pres & Director
Ms. Lori J. Braender BSBA, Esq., J.D.
Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Mr. Peter E. Boyd
Senior Vice President of IT, HR & Communications
Mr. Robert Charles Arnold
Vice President of Fin., Controller & Assistant Sec.
Cassie Jung
Senior Vice President of Operations
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep